Conatus Pharmaceuticals to Report Second Quarter 2014 Financial Results

Conatus Pharmaceuticals to Report Second Quarter 2014 Financial Results

SAN DIEGO, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc.
(Nasdaq:CNAT), a biotechnology company focused on the development and
commercialization of novel medicines to treat liver disease, today announced
that it will report financial results for the second quarter ended June 30,
2014, after the market close on Wednesday, August 13, 2014. Conatus will host
a conference call and audio webcast at 4:30 p.m. Eastern Time on Wednesday,
August 13, 2014, to discuss the financial results and provide a corporate

To access the conference call, please dial 877-312-5857 (domestic) or
970-315-0455 (international) at least five minutes prior to the start time and
refer to conference ID 83518440. A live and archived audio webcast of the call
will also be available in the Investor Center of the Company's website at

About Conatus Pharmaceuticals Inc.

Conatus is a biotechnology company focused on the development and
commercialization of novel medicines to treat liver disease. Conatus is
developing emricasan as a first-in class, orally active caspase protease
inhibitor designed to reduce the activity of enzymes that mediate inflammation
and cell death, or apoptosis. Conatus believes that by reducing the activity
of these enzymes, emricasan has the potential to interrupt the progression of
liver disease. For additional information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended. All statements
other than statements of historical facts contained in this press release,
including statements regarding anticipated clinical development plans and
proposed activity of emricasan in patients with liver disease, are
forward-looking statements. In some cases, you can identify forward-looking
statements by terms such as "may," "will," "should," "expect," "plan,"
"anticipate," "could," "intend," "target," "project," "contemplates,"
"believes," "estimates," "predicts," "potential" or "continue" or the negative
of these terms or other similar expressions. These forward-looking statements
speak only as of the date of this press release and are subject to a number of
risks, uncertainties and assumptions, including: changes in the planned use of
proceeds from Conatus' initial public offering; Conatus' ability to maintain
sufficient capital to advance the clinical development of emricasan and fund
Conatus' operations; Conatus' reliance on third parties to conduct its
clinical trials, manufacture its preclinical and clinical drug supplies and
manufacture commercial supplies of emricasan, if approved; potential adverse
side effects or other safety risks associated with emricasan; results of
current and future clinical trials of emricasan; the uncertainty of the FDA
approval process and other regulatory requirements; the potential for
competing products to limit the clinical trial enrollment opportunities for
emricasan in certain indications; and those described in Conatus' prior press
releases and the periodic reports it files with the Securities and Exchange
Commission. The events and circumstances reflected in Conatus' forward-looking
statements may not be achieved or occur and actual results could differ
materially from those projected in the forward-looking statements. Except as
required by applicable law, Conatus does not plan to publicly update or revise
any forward-looking statements contained herein, whether as a result of any
new information, future events, changed circumstances or otherwise.

         Alan Engbring, Conatus Pharmaceuticals
         (858) 376-2637,
         Mariesa Kemble, Sam Brown Inc.
         (608) 850-4745,
Press spacebar to pause and continue. Press esc to stop.